A Double-Blind Multicenter Group Comparative Study of the Efficacy and Safety of Nedocromil Sodium in the Management of Asthma: Discussion (1)
The data presented indicate a beneficial effect of nedocromil sodium in adult patients with asthma — buy asthma inhaler. Neither the severity of the asthma nor the atopic status of the patients appeared to be a factor in this response. The results from the first two weeks of this study indicate that the addition of nedocromil sodium to the therapy of patients maintained on SRT and inhaled p2 can produce rapid, significant improvements in subjective assessments of disease symptoms and severity (day and night-time asthma, cough), concomitant bronchodilator usage, and objective measurements of lung function.
Patients had been asked to remain taking their maintenance regimen, but a spontaneous reduction in bronchodilator usage occurred in the nedocromil sodium-treated group accompanied by a rapid improvement (on or before the third day of treatment) in symptomatology. The early onset of action of nedocromil sodium had not been expected and was not predictable from knowledge of other nonsteroidal treatments. This represented a real change in status, reinforced by the significant improvements in pulmonary function and assessment of asthma severity at the week 2 clinic visit. The difference between improvements in pulmonary function at the week 2 clinic visit and the diary card (weeks 1 to 2) may be due to the different times at which patients were asked to abstain from bronchodilators before testing. Residual bronchodilatation from SRT could have masked the effect of nedocromil sodium on the diary card measurements but not at the clinic visit. If nedocromil sodium had increased baseline pulmonary function, this could account for the plateau of response on withdrawal of SRT and oral p2.